Three biotech stocks have plenty of potential, John Schroer of Allianz Global Investors says.» Read More
So, Carl Icahn is grabbing headlines this week over his new battle with Yahoo and how Boone Pickens is backing him up now, too. But Icahn has his finger in a lot of pies. He's still in a proxy fight with Biogen Idec where he's trying to get his people on the Board at the upcoming shareholder meeting on June 19th.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
Stocks closed mixed in thin trading Tuesday as the tide turned in technology's favor. Airline stocks rose as oil prices receded. Merck skidded after an FDA rejection.
Stocks pushed higher Tuesday despite concerns about interest rates ahead of the Federal Reserve's decision. Merck skidded after an FDA rejection. Airline stocks rose as oil prices receded.
Stocks declined Tuesday amid concerns about interest rates and a slide in consumer confidence. Merck dragged on the Dow industrials after the FDA rejected a key cholesterol drug.
Genentech and Biogen Idec said a key study of Rituxan did not meet its main goal of a response in patients with systemic lupus erythematosus, commonly called lupus.
Investors are finding no solace in Merck's reaffirmation that it'll still hit its earnings numbers this year. Instead they're punishing the stock after the company announced what everyone is calling a surprise and a significant setback.
Was Pfizer's miss, a prescription for disaster in Big Pharma? Should you sell drug makers ahead of earnings next week?
It's not Carl Icahn. Earlier this month I blogged about a mysterious institutional investor taking a big stake in the ever-popular biotech Dendreon. DNDN's CFO was quoted as saying the secret admirer was familiar with biotech leading some to speculate it might be the billionaire activist investor who has taken stakes in Biogen-Idec, MedImmune and ImClone, just to name a few.
Genentech stock is on a tear this year and analysts are expecting double-digit sales growth for most of the biotech's key drugs this quarter. Can Genentech keep it up?
Pfizer treats us for everything from high cholesterol to impotence but in an ironic twist, it’s very sick itself. What’s the prescription for getting shares of Pfizer out of triage?
With a strong quarter expected next week, the shorts are on the run.
In Friday’s Web Extra find out how the traders recommend playing Wal-Mart, Costco, Pfizer, Amgen and Genentech in the week ahead.
I thought I was finished with the post-Pfizer analyst meeting reaction with yesterday's post, but when an extraordinarily bearish 77-page research note from Credit Suisse big pharma analyst Catherine Arnold arrived in my inbox this morning, I had to do one more installment. She thinks Pfizer should buy Wyeth or Amgen...
Embargoes imposed by scientific groups and medical journals will once again be put to the test over the next couple of months.
Bernanke hinted at more rate cuts in his testimony to Congress, the dollar sunk to a new all-time low and Apple jumped higher after hours. Get the day's biggest stories right here.
As we sit here closely monitoring the wires and waiting for word out of Genentech and/or the FDA about a decision on Avastin for breast cancer, it seemed like as good a time as any to once again post some samples of a flood of recent emails from readers--the good, the bad and the ugly.
Stocks rose for their third consecutive gain to complete their longest winning streak of the year so far on strength in oil, tech and other familiar trends. Also, breaking biotech news on Genentech and Biogen in the Word on the Street.
In Wednesday’s Web Extra, Pete Najarian reveals how he’s playing biotech. Could these stocks be just what the doctor ordered?
I'm blogging a little later than usual because I got sidetracked by the breaking news on the government stopping part of a big diabetes drug study over safety concerns--more people died in a group that was being intensively treated to get their blood sugar levels below current recommendations.